Home World News Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients... World News Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 392 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine... March 1, 2024 Mom Goes From Worried To Mortified After Finding Dark Brown Spot... June 4, 2019 Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer November 24, 2021 Colorectal Cancer Screening: Where Does the Shield Liquid Biopsy Fit In? October 11, 2024 Load more HOT NEWS Journalist Is Now Cancer-Free After Receiving Diagnosis On Facebook Live Teen Quarterback Scores 8 Touchdowns A Day After His Mom Dies... Mother and Daughter Graduate Nursing Masters Programs Together After Breast Cancer... FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or...
